Breaking News

AstraZeneca to Invest $15 Billion in China Through 2030

Will expand AstraZeneca’s capabilities to discover, develop, and manufacture transformative new treatments in China.

Author Image

By: Charlie Sternberg

Associate Editor

AstraZeneca has announced a $15 billion investment in China through 2030 to expand medicines manufacturing and R&D. This investment will leverage China’s scientific expertise, advanced manufacturing, and China-UK healthcare ecosystem collaborations to deliver treatments to patients across China and globally. Pascal Soriot, CEO, AstraZeneca, said: “Today’s landmark investment of $15 billion begins an exciting next chapter for AstraZeneca in China, which has become a critical contributor to...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics